Respiratory infectious diseases frequently erupt on a global scale, with RNA viruses, such as SARS-CoV-2, RSV, and influenza viruses, posing challenges to vaccine development due to their high mutation rates. Traditional vaccine development cycles are lengthy and struggle to keep pace with rapidly evolving viruses, whereas messenger RNA (mRNA) vaccines have demonstrated significant advantages due to their short development periods, straightforward production, and low costs. After the outbreak of the COVID-19 pandemic, multiple mRNA vaccines, including Pfizer-BioNTech and Moderna, rapidly received emergency use authorization, validating their feasibility. The Nobel Prize in Physiology or Medicine in 2023 was awarded to Katalin Karikó and Drew Weissman, underscoring the efficacy of mRNA vaccine technology. In 2024, the U.S. Food and Drug Administration (FDA) approval of Moderna's respiratory syncytial virus (RSV) mRNA vaccine marked the immense potential of mRNA technology in vaccine innovation. This review article summarizes the design, clinical research, and future challenges of mRNA vaccines for respiratory viruses, delving into antigen design, mRNA delivery systems, and advancements in vaccines for multiple respiratory viruses, including innovations in self-amplifying mRNA and circular mRNA vaccines. Additionally, the development of combination vaccines is underway, aiming to provide protection against multiple viruses through a single administration. Despite the significant progress in mRNA vaccine development, challenges remain regarding raw material costs, stability, and delivery efficiency. In the future, with technological advancements and the accumulation of clinical experience, the design strategies and delivery systems of mRNA vaccines are expected to be continuously optimized, thereby enhancing their safety and efficacy.
| [1] |
Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657-663.
|
| [2] |
Lv Q, Zhou S, Qi F, et al. Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants. Animal Model Exp Med. 2022;5(1):89-93.
|
| [3] |
Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654-656.
|
| [4] |
Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection. Nature. 2022;608(7923):593-602.
|
| [5] |
Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent omicron RBD evolution. Nature. 2023;614(7948):521-529.
|
| [6] |
Uraki R, Ito M, Furusawa Y, et al. Humoral immune evasion of the omicron subvariants BQ. 1.1 and XBB. Lancet Infect Dis. 2023;23:30-32.
|
| [7] |
Wayment-Steele HK, Kim DS, Choe CA, et al. Theoretical basis for stabilizing messenger RNA through secondary structure design. Nucleic Acids Res. 2021;49(18):10604-10617.
|
| [8] |
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279.
|
| [9] |
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.
|
| [10] |
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416.
|
| [11] |
Moderna Receives U.S. FDA approval for RSV vaccine mRESVIA(R) (modernatx.com).
|
| [12] |
Wilson E, Goswami J, Baqui AH, et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med. 2023;389(24):2233-2244.
|
| [13] |
Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 omicron variant. Cell. 2022;185(3):457-466.e4.
|
| [14] |
Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817-838.
|
| [15] |
Espeseth AS, Cejas PJ, Citron MP, et al. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. NPJ Vaccines. 2020;5(1):16.
|
| [16] |
Arevalo CP, Bolton MJ, Le Sage V, et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. 2022;378(6622):899-904.
|
| [17] |
Russell CA, Fouchier RAM, Ghaswalla P, et al. Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines. Hum Vaccin Immunother. 2024;20(1):2336357.
|
| [18] |
Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21(3):162-177.
|
| [19] |
Morais P, Adachi H, Yu YT. The critical contribution of Pseudouridine to mRNA COVID-19 vaccines. Front Cell Dev Biol. 2021;9:789427.
|
| [20] |
Leppek K, Byeon GW, Kladwang W, et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat Commun. 2022;13(1):1536.
|
| [21] |
Rappaport AR, Hong SJ, Scallan CD, et al. Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Nat Commun. 2022;13(1):3289.
|
| [22] |
Wayne CJ, Blakney AK. Self-amplifying RNA COVID-19 vaccine. Cell. 2024;187(8):1822-1822.e1.
|
| [23] |
Oda Y, Kumagai Y, Kanai M, et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect Dis. 2024;24(4):351-360.
|
| [24] |
Xie J, Ye F, Deng X, et al. Circular RNA: a promising new star of vaccine. J Transl Int Med. 2023;11(4):372-381.
|
| [25] |
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19. https://investors.modernatx.com/
|
| [26] |
COVID-19 Annual Report: Important Takeaways Ahead of 2024/2025 Season. By: James Mansi, VP of Medical Affairs, Moderna. https://www.modernatx.com/
|
| [27] |
Hou X, Zaks T, Langer R, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6: 1078-1094.
|
| [28] |
Chen SP, Blakney AK. Immune response to the components of lipid nanoparticles for ribonucleic acid therapeutics. Curr Opin Biotechnol. 2024;85:103049.
|
| [29] |
Riley RS, Kashyap MV, Billingsley MM, et al. Ionizable lipid nanoparticles for in utero mRNA delivery. Sci Adv. 2021;7(3):eaba1028.
|
| [30] |
Raguram A, Banskota S, Liu DR. Therapeutic in vivo delivery of gene editing agents. Cell. 2022;185(15):2806-2827.
|
| [31] |
Su K, Shi L, Sheng T, et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nat Commun. 2024;15:5659.
|
| [32] |
Pomatto MAC, Gai C, Negro F, et al. Oral delivery of mRNA vaccine by plant-derived extracellular vesicle carriers. Cells. 2023;12(14):1826.
|
| [33] |
McMahan K, Wegmann F, Aid M, et al. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature. 2024;626(7998):385-391.
|
| [34] |
Jansen EM, Frijlink HW, Hinrichs WL, Ruigrok MJ. Are inhaled mRNA vaccines safe and effective? A review of preclinical studies. Expert Opin Drug Deliv. 2022;19(11):1471-1485.
|
| [35] |
Oudit GY, Wang K, Viveiros A, Kellner MJ, Penninger JM. Angiotensin-converting enzyme 2-at the heart of the COVID-19 pandemic. Cell. 2023;186(5):906-922.
|
| [36] |
Feng H, Yang L, Yang H, et al. A cardiotoxicity-eliminated ACE2 variant as a pan-inhibitor against coronavirus cell invasion. Mol Ther. 2024;32(1):218-226.
|
| [37] |
Burki TK. Omicron variant and booster COVID-19 vaccines. Lancet Respir Med. 2022;10(2):e17.
|
| [38] |
Kaku Y, Uriu K, Okumura K, Genotype to Phenotype Japan (G2P-Japan) Consortium, Ito J, Sato K. Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant. Lancet Infect Dis. 2024;24(10):e609.
|
| [39] |
Conde J, Langer R, Rueff J. mRNA therapy at the convergence of genetics and nanomedicine. Nat Nanotechnol. 2023;18(6):537-540.
|
| [40] |
Qu L, Yi Z, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728-1744.e16.
|
| [41] |
Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers. 2018;4(1):3.
|
| [42] |
Hsu D, Jayaraman A, Pucci A, et al. Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50–75 years: a phase 1/2, open-label, randomised trial. Lancet Infect Dis. 2024;S1473-3099(24):00493-96.
|
| [43] |
Rosas-Salazar C, Chirkova T, Gebretsadik T, et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet. 2023;401(10389):1669-1680.
|
| [44] |
Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023;23(1):e2-e21.
|
| [45] |
Falsey AR, Williams K, Gymnopoulou E, et al. Efficacy and safety of an Ad26.RSV.preF-RSV preF protein vaccine in older adults. N Engl J Med. 2023;388(7):609-620.
|
| [46] |
Kis Z, Kontoravdi C, Shattock R, et al. Resources, production scales and time required for producing RNA vaccines for the global pandemic demand. Vaccines (Basel). 2021;9(3):205.
|
| [47] |
Zhang H, Zhang L, Lin A, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. 2023;621(7978):396-403.
|
| [48] |
Wayment-Steele HK, Kim DS, Choe CA, et al. Theoretical basis for stabilizing messenger RNA through secondary structure design. bioRxiv. 2021; [Preprint]. 2021:2020.08.22.262931.
|
| [49] |
Abbasi S, Matsui-Masai M, Yasui F, et al. Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity. Mol Ther. 2024;32(5):1266-1283.
|
| [50] |
Pardi N, Krammer F. mRNA vaccines for infectious diseases—advances, challenges and opportunities. Nat Rev Drug Discov. 2024;23(11):838-861.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
PDF
